New drug hopes to speed recovery from rare nerve disease
Disease control
Recruiting now
This study tests a single dose of tanruprubart (ANX005) in 30 adults and children with Guillain-Barré syndrome (GBS), a rare nerve disorder that causes muscle weakness. The goal is to see how the drug works in the body, its early effects on symptoms, and its safety. Participants …
Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC